Background {#Sec1}
==========

Targeting optimal nutrition concerning energy goals is essential in critically ill patients, as both underfeeding and overfeeding have been associated with increased morbidity and mortality \[[@CR1]\]. Ideally, the target is based on energy expenditure (EE). However, due to the pathophysiological response to critical illness, iatrogenic interventions, and differences in body composition, EE is highly variable in and between critically ill patients \[[@CR2]\]. Frequent monitoring of EE may circumvent this problem and help to adjust the optimal amount of calories on an individual basis. At present, indirect calorimetry is considered the gold standard. However, frequently, this technique is not available and often unfeasible \[[@CR3]\].

To optimize nutritional targets without frequent monitoring of EE, it is essential to know which factors are associated with either an increase or decrease in EE.

Specific conditions expected to influence EE have been studied such as sepsis \[[@CR4]--[@CR6]\], burns \[[@CR4], [@CR7]\], trauma \[[@CR4], [@CR8]\], cerebrovascular accidents \[[@CR4], [@CR9]\], pregnancy \[[@CR10]\], body temperature \[[@CR4]\], administration of sedatives \[[@CR11]\], and therapeutic hypothermia \[[@CR4], [@CR12]\]. An increased EE has been reported in patients with sepsis, trauma, burns, fever, and pregnancy. Therapeutic hypothermia and the administration of sedatives are associated with a decrease in EE \[[@CR4]\]. However, limited information is available on the effects of neuromuscular blocking agents (NMBAs) on EE. Furthermore, it is not known whether NMBA administration affects the EE in sepsis patients similarly compared with non-sepsis patients and in relation to the baseline temperature.

This study aimed to quantify the effect of cisatracurium infusion on EE of adult critically ill patients. Also, we analyzed the effects of body temperature and sepsis on EE. Secondary endpoint was hypercaloric feeding as a consequence of muscle relaxation.

Materials and methods {#Sec2}
=====================

We performed a retrospective observational study in patients treated with cisatracurium at the mixed medical-surgical adult intensive care unit of the Gelderse Vallei Hospital, Ede, The Netherlands, between January 1, 2011, and October 31, 2016. Patients were included when they met with the following inclusion criteria: adult critically ill patients (≥ 18 years) requiring invasive mechanical ventilation and treatment with cisatracurium for at least 12 h.

Exclusion criteria were pregnancy, hypothermia induced by therapeutic temperature management, burns, and malignant hyperthermia because these conditions have a substantial effect on EE. Patients were also excluded when data on VCO~2~ were incomplete. In patients with multiple ICU admissions during the study period, data from readmissions were excluded. An ICU admission was considered readmission when the patient was admitted within 6 months from the primary ICU admission.

Administration of cisatracurium {#Sec3}
-------------------------------

Cisatracurium is the NMBA of choice for sustained neuromuscular blockade during critical illness in Gelderse Vallei Hospital. Cisatracurium was administered when indicated according to the international clinical practice guidelines for the sustained neuromuscular blockade in the adult critically ill patient \[[@CR13]\]. An infusion was started at doses of 3 μg/kg per minute and then adjusted by assessment of the train-of-four (TOF) using a peripheral nerve stimulator (TOF-watch® S, Dublin, Ireland). According to the hospital protocol, TOF measurements were performed every hour, and dosage adjustments were made to achieve a TOF level of 1 or lower. The electrodes of the TOF-watch® were placed on the other wrist daily to prevent skin lesions.

Outcome measures {#Sec4}
----------------

The primary endpoint was the total EE, expressed as kcal/day, which was measured before and during cisatracurium infusion. Indirect calorimetry was not routinely available during the study period. EE was, therefore, estimated by an adjusted version of Weir's equation using the ventilator-derived VCO~2~ (EEVCO~2~). EEVCO~2~ = 3.941 × VCO~2~(L/min) / respiratory quotient + 1.11 × VCO~2~(L/min) × 1440. The respiratory quotient was considered to be a fixed value of 0.86 \[[@CR14]--[@CR16]\]. The mechanical ventilator measured the VCO2 (Hamilton-S1, Hamilton Medical AG, Bonaduz, Switzerland), and every minute, data are automatically sent to our electronic patient data management system (MetaVision; iMDsoft MetaVision®, Tel Aviv, Israel). For each patient, the VCO~2~ was collected during the 12 h before and during the 12 h after the start of cisatracurium infusion. When patients were not admitted to the ICU 12 h before the start of cisatracurium infusion, the parameters of the available hours were used. The EEVCO~2~ was calculated every 2 h using the mean VCO~2~ measurements from the previous 2 h.

Secondary endpoint was hypercaloric feeding (\> 110% of EE) after cisatracurium infusion. We also evaluated ICU length of stay (LOS) and in-hospital mortality in patients receiving hypercaloric versus regular or hypocaloric feeding.

Calculation of nutritional goals {#Sec5}
--------------------------------

The World Health Organization/Food and Agricultural Organization of the United Nations (WHO/FAO) formulas were used to calculate caloric and protein targets by our computerized feeding protocol \[[@CR17]\]. According to BMI, the actual (BMI \< 27), corrected (BMI 27--30; regression to BMI of 27), or ideal body weight (BMI \> 30; regression to BMI 21 in women and BMI 22.5 in men) was used. An addition to the resting EE (REE) of 20% was used to correct for disease activity \[[@CR18]\].

Data collection {#Sec6}
---------------

Most parameters were routinely collected into an extensive ICU database during standard clinical care. Data extraction was performed using SAS Enterprise Guide queries (version 7.12HF1) searching our Patient Data Management System (MetaVision; iMDsoft MetaVision®, Tel Aviv, Israel, and neoZIS®, Electronic Medical Record, MI Consultancy, Katwijk, The Netherlands). Data to calculate the Charlson Comorbidity Index (CCI) \[[@CR19]\] were obtained from the quality management system for hospital mortality registration. Data verification was performed manually. Collected data were de-identified and stored on a secure hospital computer. There were no identifiable paper documents.

Data analysis and statistical considerations {#Sec7}
--------------------------------------------

Descriptive data are reported as means and standard deviation (SD) or median and interquartile range in case of skewed distributions, or as frequencies and percentages when appropriate. For the primary analysis, comparing the EE before and after cisatracurium infusion, a general linear mixed model analysis for repeated measures was performed with an autoregressive covariance structure. In this analysis, we corrected for body temperature, sedative and noradrenaline dosages, pH, PEEP, and FiO~2~ and repeated measurements.

We performed a subgroup analysis of septic and non-septic patients. We also evaluated the effects of body temperature on EE with the Pearson or Spearman rank correlation tests. The effects of sepsis on EE were analyzed through general linear mixed models, correcting for the following confounders: cisatracurium, temperature, NUTRIC score, gender, BMI, admission type, and repeated effects. Finally, we evaluated the effect of hypercaloric feeding vs. normocaloric and hypocaloric feeding on in-hospital mortality and ICU length of stay (LOS) by chi-square test and one-way ANOVA, respectively. A *p* value of \< 0.05 was considered statistically significant.

The data analyses were performed using IBM corp. SPSS statistics for Windows (version 24.0, released 2015 New York, USA).

Results {#Sec8}
=======

Patients {#Sec9}
--------

During the study period, 4247 patients were admitted to the ICU, of which 179 received cisatracurium for at least 12 h and therefore were eligible for inclusion. We excluded 57 patients according to the exclusion criteria. In total, 122 patients were enrolled in this study (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flowchart

Baseline characteristics and nutritional parameters are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, and [3](#Tab3){ref-type="table"}. The median age was 65.5 years, and 36.1% were female. The median SOFA and APACHE II scores on admission were 8 and 22, respectively. Most patients were septic (58.2%) and admitted to the ICU because of medical reasons (73%). A median ICU and hospital LOS of 15 and 23 days were found. The in-hospital mortality was 28.7%. Table 1Baseline characteristicsTotal (*n* = 122)Gender (female)*N* (%)44 (36.1)Age (years)Median \[IQR\]66 \[55--73\]BMI on admission (kg/m^2^)Median \[IQR\]27.6 \[24.0--31.0\] ▪ Malnourished (\< 18.5)*N* (%)3 (2.5) ▪ Normal (18.5--24.9)33 (27.0) ▪ Overweight (25--29.9)44 (36.1) ▪ Obese (30--34.9)26 (21.3) ▪ Morbidly obese (\> 35)16 (13.1)Admission type*N* (%) ▪ Medical89 (73.0) ▪ Emergency surgery16 (13.1) ▪ Elective surgery17 (13.9)Sepsis*N* (%)72 (59.0)Charlson Comorbidity IndexMedian \[IQR\]4 \[2--5\]SOFA score on admissionMedian \[IQR\]8 \[5--9.5\]APACHE II score on admissionMedian \[IQR\]21.5 \[19 -- 26.25\]ICU length of stay (days)Median \[IQR\]15 \[8--26.5\]Hospital length of stay (days)Median \[IQR\]23 \[12--42\]In-hospital mortality*N* (%)36 (29.5)*BMI* body mass index, *IQR* interquartile range, *SOFA* Sequential Organ Failure Assessment, *APACHE* acute physiology and chronic health evaluation, *ICU* intensive care unit Table 2Baseline characteristics before and after cisatracurium administrationBefore cisatracurium (*n* = 122)After cisatracurium (*n* = 122)*p* valuePEEP (cmH~2~O)Mean ± SD9.8 ± 3.010.6 ± 3.90.012FiO~2~ (%)Median \[IQR\]49 \[40--59\]44.5 \[36--55\]0.008Noradrenalin (μg/kg/min)Mean ± SD0.16 ± 0.640.33 ± 1.250.178Propofol (mg/h)Mean ± SD44.9 ± 73.142.2 ± 70.80.570Midazolam (mg/h)Mean ± SD7.5 ± 5.39.0 ± 5.8\< 0.001Morphine (mg/h)Mean ± SD1.2 ± 1.31.5 ± 1.4\< 0.001pHMean ± SD7.31 ± 0.117.32 ± 0.100.600TOFMedian \[IQR\]NA0 \[0--1\]NA*PEEP* positive end-expiratory pressure, *FiO*~*2*~ fraction of inspired oxygen, *TOF* train of four, *NA* not applicable Table 3Nutritional parametersTotal (*n* = 122)NUTRIC score at admissionMedian \[IQR\]6 \[4--7\] ▪ Low risk (0--4 points)*N* (%)35 (29.9) ▪ High risk (5--9 points)*N* (%)82 (71.1)Nutritional route^a^ *N* (%) ▪ Enteral91 (91.9) ▪ Parenteral6 (6.1) ▪ Both2 (2.0)Average caloric intake (kcal/day)^b^Mean (±SD)831 (612)*NUTRIC* Nutrition Risk in Critically ill \[[@CR20]\], *IQR* interquartile range, *SD* standard deviation^a^Nutritional route during the first 24 h of ICU admission^b^Average caloric and protein intake during the first day of cisatracurium administration (kcal/day)

Primary outcome {#Sec10}
---------------

The mean EE was 1974 kcal/day before cisatracurium infusion (= control period) and 1888 kcal/day during cisatracurium infusion resulting in a mean difference of − 85.9 kcal (95% CI − 151.8 to − 20.0; *p* = 0.011). After correction for body temperature, sedative and noradrenalin dosages, pH, PEEP, and FiO~2~ in mixed model multivariable analysis, the significant treatment effect of cisatracurium on EE persisted, with a mean difference of − 132.0 kcal (95% CI − 212.0 to − 52.0; *p* = 0.001). Cisatracurium significantly lowered EE by 6.6% (95% CI 2.6--10.6%). The results are depicted in Fig. [2](#Fig2){ref-type="fig"}. Fig. 2Energy expenditure before and during continuous cisatracurium infusion

### Subgroup analysis of sepsis patients {#Sec11}

In the subgroup of sepsis patients, cisatracurium reduced EE from 2058 kcal/day to 1932 kcal/day (mean difference of − 125.7 kcal; 95% CI − 243.0 to − 8.4; *p* = 0.036). In the subgroup of non-sepsis patients, cisatracurium reduced EE from 1932 kcal/day to 1795 kcal/day (mean difference − 137.2 kcal; 95% CI − 243.0 to − 31.4; *p* = 0.011). In both analyses, adjustment for body temperature, sedative and noradrenaline dosages, pH, PEEP, and FiO~2~ were performed.

Effect of body temperature on EE {#Sec12}
--------------------------------

A significant non-linear positive association between body temperature and EE was found (Spearman's rho = 0.486, *p* \< 0.001; Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Association between body temperature and energy expenditure

Effect of sepsis on EE {#Sec13}
----------------------

Mean EE was 1805 kcal (95% CI 1721--1888) in non-septic patients and 1909 kcal (95% CI 1838--1978) in septic patients (*p* = 0.062). In mixed-model multivariable analysis, a significantly lower EE was observed in non-septic patients than in septic patients (mean difference − 120.6 kcal, 95% CI − 200.5 to − 40.8; *p* = 0.003).

Hypercaloric feeding {#Sec14}
--------------------

Only seven patients (5.7%) received \> 110% of their caloric target (estimated by EEVCO~2~) on the first day of cisatracurium infusion. Twenty patients (16.4%) received between 80 and 110% of their caloric target, while 95 patients (77.9%) were fed hypocalorically (\< 80% of caloric target). Because of the small number of patients with hypercaloric intake, no associations between hypercaloric intake and ICU LOS or mortality were calculated.

Discussion {#Sec15}
==========

We studied the effect of cisatracurium infusion on EE in a cohort of 122 adult critically ill patients. Cisatracurium infusion lowered EE as estimated by the VCO~2~ method by 6.6%.

NMBAs act by interfering with the binding of acetylcholine to the motor endplate in the synaptic cleft of the neuromuscular junction, thereby ultimately preventing muscle contraction. Indications for the continuous infusion of NMBAs during critical illness comprise severe acute respiratory distress syndrome (ARDS) (PaO~2~/FiO~2~ \< 150), overt shivering during therapeutic hypothermia, and other life-threatening situations associated with profound hypoxemia, respiratory acidosis, or hemodynamic compromise in case of failure of other measures such as deep sedation \[[@CR13]\]. Cisatracurium is one of the most widely used NMBAs for continuous infusion as it can also be used in patients with hepatic or renal insufficiency \[[@CR21]\].

Due to the blocking of muscle contractions and as a consequence of the subsequent lower muscular heat production, NMBAs should conceptually reduce EE. However, this hypothesis has not been studied in ICU patients with the previously described indications for the use of continuous NMBA infusion. Overall, only one earlier study has evaluated the effects of NMBAs on EE in adults, reporting a significant increase in EE of 18.6% after discontinuation of pancuronium in patients with severe head injury \[[@CR22]\]. Additionally, one study investigated the effects of NMBA infusion (vecuronium, pancuronium, and atracurium) in 20 critically ill children reporting a significant reduction of 10.3% of EE 1 h after infusion of NMBAs \[[@CR23]\].

Effect of body temperature on EE {#Sec16}
--------------------------------

We observed a non-linear positive association between body temperature and EE. Four small previous studies reported an association between body temperature and EE in critically ill patients \[[@CR4], [@CR24], [@CR25]\]. A reduction of 6.6% of EE per 1 °C decrease at temperatures below 36 °C and an increase of 8.2% per 1 °C at temperatures above 37 °C have been reported \[[@CR24], [@CR25]\].

Effect of sepsis on EE {#Sec17}
----------------------

We observed a higher EE in septic patients than in non-septic patients. This was in line with our expectations based on previous studies in which EE in septic patients was 102--198% of EE in non-septic patients \[[@CR4]\]. However, a recent observational study in 205 patients found no differences in EE between septic and non-septic patients (1434 vs. 1430 kcal/day) \[[@CR20]\].

Strengths and weaknesses {#Sec18}
------------------------

This is the largest cohort of critically ill patients in which the effects of NMBAs on EE have been studied. The effects of NMBAs, especially cisatracurium, in this specific patient population have not been studied before. A large number of patient variables were available with few missing data, providing enough data to perform rigorous multivariable and repeated measure analyses.

However, our study has several limitations. Indirect calorimetry was not routinely available during the study period. Therefore, EE was calculated using VCO~2~ obtained from the mechanical ventilator. Calculation of EE from VCO~2~ has been demonstrated to be more accurate than predictive equations, but less than indirect calorimetry. Finally, limitations related to the retrospective design may potentially have introduced bias and residual confounding.

Clinical implications {#Sec19}
---------------------

As cisatracurium reduces EE, reduction of caloric intake after the start of NMBAs should be considered, especially in those patients that are on full feeding or considered to reach this target soon, because they are at risk of hypercaloric feeding and associated harm. Before we designed the study, we expected, due to the drop in EE induced by the NMBA, that some of the patients would be overfed. Based on the results, we noticed that a reduction of EE by NMBA could induce an almost 10% overfeeding risk in individual patients. In daily practice, this did not occur as the patients were not on nutrition target. Thus, for most patients, adjustment may not be necessary as in our analysis the reduction of EE found was only 6.6% and hypercaloric feeding was only present in 5.7%, while most other patients were fed (77.9%) hypocalorically after initiation of cisatracurium infusion.

Although not the focus of our present study, it should be noted that the recent ROSE trial, studying the effect of early neuromuscular blockade (48-h continuous infusion of cisatracurium) with concomitant heavy sedation, compared with usual care, did not result in a significant mortality difference at 90 days in patients with moderate to severe acute respiratory distress syndrome in contrast to an earlier RCT \[[@CR26], [@CR27]\]. This trial was stopped early at the second interim analysis for futility. This study may lead to reevaluation of the use of NMBAs in severe respiratory failure.

Conclusions {#Sec20}
===========

Our data suggest that continuous infusion of cisatracurium in mechanically ventilated ICU patients is associated with a significant reduction in EE as estimated by the VCO~2~ method, although the magnitude of the effect is small. Sepsis and higher body temperature are associated with increased EE. Cisatracurium infusion is associated with overfeeding in only a minority of patients, and therefore, in most patients no reductions in caloric prescription are necessary.
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